← Back to Search

Precursor of Dopamine

Testing on-levodopa for Parkinson's Disease

Phase 2 & 3
Waitlist Available
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up outcome measures will be assessed at 1 year
Awards & highlights

Study Summary

This trial will look at how levodopa affects the cardiovascular autonomic function in patients with Parkinson's disease with and without neurogenic orthostatic hypotension.

Eligible Conditions
  • Parkinson's Disease
  • Orthostatic Hypotension

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~outcome measures will be assessed at 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and outcome measures will be assessed at 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in systolic blood pressure from supine to tilt at 3 minutes
Secondary outcome measures
Validated index of baroreflex cardiovagal function
Validated index of sympathoneural function

Trial Design

2Treatment groups
Experimental Treatment
Group I: Testing on-levodopaExperimental Treatment1 Intervention
Participants will undergo autonomic testing one hour after taking their regular morning dose of levodopa.
Group II: Testing off-levodopaExperimental Treatment1 Intervention
Participants will undergo autonomic testing at least twelve hours after taking their last dose of levodopa.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Autonomic testing on and off levodopa
2022
Completed Phase 3
~40

Find a Location

Who is running the clinical trial?

University of UtahLead Sponsor
1,104 Previous Clinical Trials
1,782,493 Total Patients Enrolled
~13 spots leftby Jun 2025